Company Quick10K Filing
XsunX
10-Q 2020-06-30 Filed 2020-08-21
10-Q 2020-03-31 Filed 2020-05-14
10-Q 2019-12-31 Filed 2020-01-24
10-K 2019-09-30 Filed 2019-12-20
10-Q 2019-06-30 Filed 2019-08-19
10-Q 2019-03-31 Filed 2019-05-14
10-Q 2018-12-31 Filed 2019-02-01
10-K 2018-09-30 Filed 2019-01-07
10-Q 2018-06-30 Filed 2018-08-14
10-Q 2018-03-31 Filed 2018-05-21
10-Q 2017-12-31 Filed 2018-02-12
10-K 2017-09-30 Filed 2017-12-21
10-Q 2017-06-30 Filed 2017-08-14
10-Q 2017-03-31 Filed 2017-05-15
10-Q 2016-12-31 Filed 2017-02-21
10-K 2016-09-30 Filed 2016-12-14
10-Q 2016-06-30 Filed 2016-08-15
10-Q 2016-03-31 Filed 2016-05-16
10-Q 2015-12-31 Filed 2016-02-12
10-K 2015-09-30 Filed 2016-01-08
10-Q 2015-06-30 Filed 2015-08-14
10-Q 2015-03-31 Filed 2015-05-20
10-Q 2014-12-31 Filed 2015-02-17
10-K 2014-09-30 Filed 2015-01-13
10-Q 2014-06-30 Filed 2014-08-18
10-Q 2014-03-31 Filed 2014-05-19
10-Q 2013-12-31 Filed 2014-02-14
10-K 2013-09-30 Filed 2014-01-14
10-Q 2013-06-30 Filed 2013-08-12
10-Q 2013-03-31 Filed 2013-05-13
10-Q 2012-12-31 Filed 2013-02-14
10-K 2012-09-30 Filed 2013-01-11
10-Q 2012-06-30 Filed 2012-08-14
10-Q 2012-03-31 Filed 2012-05-18
10-K 2011-09-30 Filed 2011-12-29
10-Q 2011-06-30 Filed 2011-08-15
10-Q 2011-03-31 Filed 2011-05-13
10-Q 2010-12-31 Filed 2011-02-14
10-K 2010-09-30 Filed 2010-12-29
10-Q 2010-06-30 Filed 2010-08-13
10-Q 2010-03-31 Filed 2010-05-17
10-Q 2009-12-31 Filed 2010-02-16
10-K 2009-09-30 Filed 2010-01-13
8-K 2020-10-21 Officers
8-K 2020-10-15 Officers
8-K 2020-09-04 Enter Agreement, M&A, Sale of Shares, Shareholder Rights, Amend Bylaw, Exhibits
8-K 2020-08-25 Amend Bylaw, Exhibits
8-K 2020-06-02
8-K 2020-03-18
8-K 2019-11-18
8-K 2018-05-09
8-K 2018-01-16

XsunX Financials

XSNX Metrics, Comps, Filings

Quarterly | Annual

Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Cantabio Pharmaceuticals (CTBO) 0 0.9 -474% 326 2,215 0 0 -1,543 -331 -283
Natcore Technology (NXT)
Nutra Pharma (NPHC) 0 71% -0.2 -2,939% 252 5,614 106 75 -7,398 -6,591 1,498
Premier Biomedical (BIEI) 0 58% -0.3 -183% 186 2,304 13 8 -340 -238 75
Nate's Food (NHMD) 0 92% -0.1 -6,857% 7 825 3 3 -481 -455 30
Amplitude Healthcare (AMHCU)
Galileo Acquisition (GLEO)
GH Capital (GHHC) 0 66% -0.0 -2,680% 89 331 211 139 -2,374 -2,374 59
Life Clips (LCLP) 0 135% -0.7 -21,823% 16 9,270 -86 -116 -3,494 -3,182 2,355
Sunshine Biopharma (SBFM) 0 30% 0.1 -864% 146 889 130 38 -1,264 -1,160 -82
New You (NWYU)
VNUE (VNUE) 0 0% -2.0 -621% 168 3,666 200 0 -1,042 -634 1,242
Electromedical Technologies (ELCQ)
DigitalTown (DGTW) 0 12,618% 0.0 -16,557% 34 2,761 -2 -220 -5,706 -5,268 -34
Angiosoma (SOAN) 0 64% -0.2 -475% 142 828 0 0 -675 -315 66
XsunX (XSNX) 0 47% 0.1 1,089% 215 2,451 1,609 753 2,344 2,417 194
Pacific Ventures (PACV) 0 25% -3.8 -65% 1,799 5,073 3,514 883 -1,171 -615 2,318
Anchiano Therapeutics (ANCN)
X Rail Entertainment (XREE) 0 -0.1 -1,441,401% 0 3,429 0 0 -5,261 -5,732 345
GIFA (FRFS) 0 63% -0.9 43% 80 362 98 62 34 34 -30

Balance Sheet ($'000)2011-06-302011-12-312012-03-312012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash14825784538393739455157519924337973643422112445323132186418644608
Accounts Receivable316582020192203105334170100137235247198
Inventory41715
PP&E52342579285285285320289264100100100100100100943030303030303131131313232344
Assets437169229601582558525152191151255691346467951071706266146209124481833154154228283311215
Accounts Payable14619519314417315114714814112812812918280764287116504710820915784114113156134143148150129
Long-Term Debt16219211198220198195200201202
Liabilities7016387897529751,0049839441,0221,0859799721,0147906459741,0187988309069941,0038771,0939541,3097,7014,7923,4212,9413,4302,451
Stockholders' Equity-264-469-559-151-392-446-457-793-831-934-724-903-880-726-578-879-911-628-767-840-848-794-753-1,044-936-1,276-7,548-4,638-3,192-2,658-3,118-2,236
Income Statement ($'000)2011-06-302011-12-312012-03-312012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue0000003111420924337532027820337353122394538160828051393387476296449
Cost of Revenue307962201314242156159205377329936478514326308235232194195
Gross Profit135147-73426178122451681649951748231372585151245102254
R&D4732281516273683-240-3000
SG&A23820416812916111213113912941181341301251321251271221091271141111011179696174112120139
Tax00000000000000000000000000000
Net Income-290-448-289-535-994-297-697-1,057-375252-39423-857-64-423-31160-240-132-3633-160-336-67-459-6,2721,406482-460916
Cash Flow ($'000)2011-06-302011-12-312012-03-312012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-137-45-95-137-109-101-137-90-136-6-37-151-4627-46-19-80-27110-63-12-79-50-444045-3637-52
Cash Investing0-22-30-308516410000011400000-1-10-20
Cash Financing96120118140108951388010008675551940-55015-20-522504052250-5-190